Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback?

Company Overview - Eli Lilly's stock has experienced an 8% decline this year, despite impressive five-year gains of approximately 380% [1] - The stock currently trades at 43 times its trailing earnings, significantly higher than the S&P 500 average of 25 [2] Stock Performance - The stock reached highs of over $1,100 last month but has since dropped about 13% from that peak, indicating investor resistance to its premium valuation [5] - Analysts maintain a consensus price target of just under $1,230, suggesting a potential upside of around 24% from current levels over the next year [6] Business Growth - Eli Lilly's revenue exceeded $65 billion last year, marking a 45% increase from the previous year, driven by the success of its GLP-1 drugs, Zepbound and Mounjaro [7] - The company holds a market capitalization of approximately $900 billion, making it the most valuable healthcare business globally [7] Investment Considerations - With strong growth prospects and a dominant position in the GLP-1 market, Eli Lilly may still be a worthwhile investment, especially for long-term holders [8] - While waiting for a lower price could be beneficial, there is no certainty that the stock will continue to decline [8]